Tagged with Sanofi,

Global British pharma exec Paul Hudson joined the French pharma giant in 2019 and soon brought forward a new strategy aimed at focusing on first-in-class or best-in-class drugs and offloading the firm’s underperforming businesses. Since then and after weathering COVID-19 vaccine race defeat, Hudson has seen Sanofi through some significant wins…

China China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon displays of anti-government public dissent. Some observers are even speculating that the policy could have a greater impact on the…

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…

Europe Pharma and biotech companies have demonstrated their commitment to diversity, equity and inclusion (DEI), particularly with respect to gender equality with more and more women in leadership positions. Insights from women pharma leaders in Europe.   I believe it is more important than ever to build a truly diverse and…

Global After almost four years leading Sanofi’s second largest market, China, Pius S. Hornstein moves into a global role to focus on the company’s digital transformation. “In the last 8 years, I have been witnessing the incredible opportunities that digital could unlock …” he said in a LinkedIn post announcing the…

Global Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to overcome. Insights from pharma industry digital transformation leaders. Industry is on a dedicated and focused journey to leverage data and…

Spain Sanofí’s general manager for Spain, Margarita Lopez Acosta, comments on the company’s “Play to Win” strategy, the presence of the French giant in Spain and the leading role of the country in clinical trials. She also explains possible solutions to the challenges around access to innovation in Spain.  Both the…

Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…

Global The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT US Pharma and Biotech Summit Sanofi’s CEO Paul Hudson demonstrated that the company is not just riding the current wave but continuing to innovate on…

Europe Having moved early on a promising phase II monoclonal antibody, Almirall is inching closer to entering the Sanofi-dominated European market for eczema after posting, along with Eli Lilly, positive phase III results for Lebrikizumab. The Catalan company says it is on track for a 2023 launch on the continent; Lilly…